Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

A Multinational, Comparative Phase III Clinical Trial to Assess the Efficacy (Immunogenicity) and Safety of NBP607-QIV (0.5 mL) (Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine) in Children Aged 6 to 35 Months

This study assesses immunogenicity and safety of NBP607-QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled, and each subject is administered with single or two doses of vaccines depending on previous vaccination history.

Study Overview

• Status: Completed
• Conditions: Influenza
• Intervention / Treatment: Biological: NBP607-QIV; Biological: Agrippal

Detailed Description

This is a multi-national, multi-center, randomized, double blinded, parallel-group study to assess the immunogenicity and safety of NBP607-QIV compared to Agrippal which are indicated for active immunization for the the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled. Each subject is administered with single or two doses of vaccines depending on previous vaccination history, and randomly assigned in 2:1 ratio.

Stratified randomization for trial site and age strata is used to achieve the balance of treatment assignment.

Total of three or five visits are scheduled depeding on dosing schedule. For subjects assigned to single-dose vaccination schedule, blood sampling is conducted for immunogenicity assessment before and 4 weeks after single vaccination at Visit 1 and 3 respectively. Safety is monitored 3 days, 4 weeks after vaccination through Visit 2* and 3 (* telephone contact). For subjects assigned to two-dose vaccination schedule, blood sampling is conducted before first vaccination and 4 weeks after second vaccination at Visit 1 and Visit 5 respectively. Safety is monitored 3 days, 4 weeks after each vaccination through Visit 2*, 3, 4*, and 5 (* telephone contact)

• Study Type: Interventional
• Enrollment (Actual): 676
• Phase: Phase 3

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seongnam-si
    • Gyeonggi-do, Seongnam-si, Korea, Republic of, 13494
      • SK Bioscience

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 2 years (Child)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Children aged 6 to 35 months
• Those who were normal gestational age at birth (for children aged 6 months to <1 year)
• Those who have provided written informed consent to study participation and compliance with study instructions after being informed of and understand details of the study

Exclusion Criteria:

• Those with any immunodeficiency disease or malignancy
• Those with hypersensitivity to vaccination
• Those who are contraindicated for intramuscular injection due to thrombocytopenia or other coagulopathy
• Those with history of treatment with any of immunosuppressants or immunoregulators within 12 weeks prior to screening
• Those with history of receiving blood product or treatment with immunoglobulin within 24 weeks prior to screening
• Those with history of influenza vaccination within 24 weeks prior to screening
• Those with any severe chronic conditions that interfere with study participation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NBP607-QIV; One or two doses of 0.5mL of NBP607-QIV by intramuscular injection	Biological: NBP607-QIV; Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
Active Comparator: Agrippal; One or two doses of 0.25mL of Agrippal by intramuscular injection	Biological: Agrippal; Influenza virus surface antigens of three strains (trivalent)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post-vaccination GMT(Geometric Mean Titer) by HI(Hemagglutination-inhibition) assay for the common strains (A/H1N1, A/H3N2, and B/Victoria)	Post-vaccination GMT will be adjusted for pre-vaccination titer	4 weeks after last IP(Investigational Product) vaccination
Seroconversion rate by HI assay for the common strains (A/H1N1, A/H3N2, and B/Victoria)	Seroconversion rate is defined as the proportion of subjects who meet either of the following criteria: Post-vaccination HI titer of ≥1:40 for subjects with pre-vaccination HI titer of <1:10; Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥1:10	4 weeks after last IP(Investigational Product) vaccination
Seroconversion rate by HI assay for the exclusive strain (B/Yamagata)	Seroconversion rate is defined as the proportion of subjects who meet either of the following criteria: Post-vaccination HI titer of ≥1:40 for subjects with pre-vaccination HI titer of <1:10; Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥1:10	4 weeks after last IP(Investigational Product) vaccination
GMR(Geometric mean ratio) by HI assay for the exclusive strain (B/Yamagata)	The fold-rise of the geometric mean HI titer from pre- to post-vaccination	4 weeks after last IP(Investigational Product) vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Seroprotection rate by HI assay for all strains	Seroprotection rate is defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40	4 weeks after last IP(Investigational Product) vaccination
CHMP(Committee for Medicinal Products for Human Use) criteria assessment for the common strains (A/H1N1, A/H3N2, and B/Victoria)	CHMP criteria for seroconversion rate, GMR(Geometric Mean Ratio) will be assessed	4 weeks after last IP(Investigational Product) vaccination
Consistency of immunogenicity among countries	Post-vaccination GMT and seroconversion rate for the common strains (A/H1N1, A/H3N2, and B/Victoria), and CHMP criteria for seroconversion rate and GMR for the exclusive strain (B/Yamagata) will be assessed	4 weeks after last IP(Investigational Product) vaccination
Percentage of participants with Adverse Events(AEs)	Incidence rate of Solicited AE, unsolicited AE, SAE(Serious Adverse Event) will be assessed	7 days for Solicited AE and 4 weeks for Unsolicited AE, SAE after last IP(Investigational Product) vaccination
Vital sign	Body temperature will be assessed	4 weeks after last IP(Investigational Product) vaccination
Height	Height in centimeters will be assessed	4 weeks after last IP(Investigational Product) vaccination
Weight	Weight in kilograms will be assessed	4 weeks after last IP(Investigational Product) vaccination

Collaborators and Investigators

• Sponsor: SK Bioscience Co., Ltd.
• Investigators: Study Chair: Yun Kyung Kim, MD, Korea University

Study record dates

Study Major Dates

• Study Start (Actual): October 25, 2018
• Primary Completion (Actual): July 12, 2019
• Study Completion (Actual): July 12, 2019

Study Registration Dates

• First Submitted: October 10, 2018
• First Submitted That Met QC Criteria: October 10, 2018
• First Posted (Actual): October 15, 2018

Study Record Updates

• Last Update Posted (Actual): May 11, 2022
• Last Update Submitted That Met QC Criteria: May 9, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human
• Other Study ID Numbers: NBP607-QIV_005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No